Navigation Links
Egenix, Inc. Appoints Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee
Date:10/23/2013

MILLBROOK, N.Y., Oct. 23, 2013 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee.

Dr. Fury is a Medical Oncologist in The Department of Medicine at Memorial Sloan-Kettering. Since 2006 Dr. Fury has been conducting clinical research focused on mTOR/eIF4E inhibitors for Human Papilloma related head and neck cancers. He will now be participating in a collaboration with Egenix in the development of a drug for HPV.

We at Egenix are delighted to have Dr. Fury aboard.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer's. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated be a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com.


'/>"/>
SOURCE Egenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Egenix, Inc. Announces New Director, John Reid
2. Egenix, Inc. Announces New Director
3. Metamark Appoints Cornelius J. Merlini Chief Commercial Officer
4. ACTUS Appoints New Members to Its Management Team
5. Immune Design Appoints Stephen R. Brady Chief Business Officer
6. DiaVacs, Inc. Appoints Orville Kolterman, M.D. As Chief Medical Officer
7. Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
8. Solulink Appoints Life Science Industry Veteran Jack Ball as Chief Executive Officer
9. Cold Spring Harbor Laboratory Appoints Teri F. Willey to Accelerate Commercialization Efforts
10. Senn Chemicals Appoints New Chief Executive Officer
11. Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):